Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ontunisertib - AgomAb Therapeutics

Next Previous
Drug Profile

Ontunisertib - AgomAb Therapeutics

Alternative Names: AGMB-129; ORG-129

Latest Information Update: 27 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Origo Biopharma
  • Developer AgomAb Therapeutics
  • Class Anti-inflammatories; Antifibrotics; Small molecules
  • Mechanism of Action Transforming growth factor beta type I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease

Most Recent Events

  • 17 Nov 2025 Efficacy and adverse events data from the phase IIa STENOVA trial in Crohn's disease released by AgomAb Therapeutics
  • 15 Sep 2025 Agomab Therapeutics completes a phase I trial in Crohn's disease (In volunteers) in Belgium (PO) (NCT07118878) (EUCT2025-521705-40-00)
  • 12 Aug 2025 Agomab Therapeutics plans a phase I trial for Crohn's disease (In volunteers) in August 2025 (PO (NCT07118878)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top